Katherine M Bever

9PUBLICATIONS
99CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 16, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

|Jan 12, 2026
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses.

Dimitrios N Sidiropoulos, Zhehao Zhang, Jennifer N Durham

|Jan 12, 2026
A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.

Katherine M Bever, Amanda L Huff, Ludmila Danilova

|May 19, 2025
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Eric S Christenson, Won Jin Ho, Daniel Shu

|Aug 30, 2023
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer.

H Catherine Wilbur, Jennifer N Durham, Su Jin Lim

|Mar 27, 2023
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.

Eric S Christenson, Su Jin Lim, Jennifer Durham

Pageof 2

Frequent Collaborators

8 joint publications

Jennifer N Durham

7 joint publications

Elizabeth M Jaffee

6 joint publications

Daniel Laheru

6 joint publications

Dung T Le